Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0016
- Development stage
- Preclinical
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
01
Overview
SIM0016 is a small molecule drug candidate developed by Shandong Simcere Medgenn, a subsidiary of Simcere Pharmaceutical, for the treatment of Alzheimer's disease. Currently in the preclinical or IND-enabling stage, SIM0016 is designed to act as an amyloid-beta (Aβ) aggregation inhibitor. By preventing the formation of neurotoxic Aβ oligomers and the subsequent accumulation of amyloid plaques in the brain, the drug aims to mitigate neurodegeneration and cognitive decline. SIM0016 is a key component of Simcere's neuroscience pipeline, which focuses on addressing high unmet needs in neurodegenerative and cerebrovascular diseases.
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on SIM0016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0016.